Literature DB >> 6333440

Alpha 1-antitrypsin deficiency genes: contributory defect in a subset of psoriatics?

G Lipkin, M Galdston, F Kueppers.   

Abstract

Since proteolytic processes are prominent in psoriasis, sera of forty-five psoriatics were examined for alpha 1-antitrypsin (alpha 1-AT) phenotype and eighteen sera, for alpha 1-AT content and function. Five sera (11.1%) had heterozygous phenotypes (2 MZ and 3 MS), a prevalence of Z and S variants similar to that reported in nonpsoriatic populations. Two of three variants examined for content and function exhibited marked reductions. Since MZ heterozygotes are almost always, and MS phenotypes sometimes, associated with decreased serum alpha 1-AT levels, and since Z and MZ phenotypes are associated with increased hepatic fibrosis or cirrhosis, these variants may be relevant to problems of spontaneous fibrosis or methotrexate-induced hepatotoxicity in psoriasis. alpha 1-AT deficiency may also contribute to guttate flares with infection and to increased O-2 . production by psoriatic sera-stimulated polymorphonuclear leukocytes (PMNs). Although no evidence exists that psoriasis is more prevalent among persons with hypomorphic alpha 1-AT phenotypes, such defects may contribute to severity of inflammation and hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333440     DOI: 10.1016/s0190-9622(84)70216-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Alpha 1-proteinase inhibitor in psoriasis: reduced activity in symptom-free patients and during flare.

Authors:  D Barszcz; Z Zarebska; M Glińska-Ferenz; S Jabłońska; M Tigałonowa; W Gliński
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

2.  Basement membrane zone as a target for human neutrophil elastase in psoriasis.

Authors:  W Glinski; M Jarzabek-Chorzelska; M Kuligowski; M Pierozynska-Dubowska; M Glinska-Ferenz; S Jabłonska
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.